HEPA (Hepion Pharmaceuticals) OCF Margin %: 0.00% (As of Mar. 2026)


What is Hepion Pharmaceuticals OCF Margin %?

Hepion Pharmaceuticals HEPA -3.39% OCF Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Hepion Pharmaceuticals ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Hepion Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2026 was $0.58 Mil. Hepion Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Hepion Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Hepion Pharmaceuticals's current OCF Yield % is -105.56%.

The historical rank and industry rank for Hepion Pharmaceuticals's OCF Margin % or its related term are showing as below:


HEPA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Hepion Pharmaceuticals OCF Margin % Related Terms

Hepion Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals OCF Margin % Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hepion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hepion Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Hepion Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.272/0
= %

Hepion Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0.579/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Hepion Pharmaceuticals (HEPA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hepion Pharmaceuticals and its competitors. According to the industry distribution chart, Hepion Pharmaceuticals ranks #999999 out of 959 companies in the Biotechnology industry.
Is Hepion Pharmaceuticals' OCF Margin % too high?
Hepion Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, Hepion Pharmaceuticals ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Hepion Pharmaceuticals' OCF Margin % compare to AXIM and SCNI?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #999999 out of 959 companies for OCF Margin %. This places Hepion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.